105 results about "Low glucose" patented technology

In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and / or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and / or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.

A 3D printed bone defect repair scaffold loaded with extracellular matrix of mesenchymal stem cells is provided, its preparation method includes: dissolving gelatin, sodium alginate and 58S bioglass in water to obtain a solution, stirring the solution evenly to obtain 3D printing slurry, and performing 3D printing; chemically cross-linking the semi-finished scaffold with a calcium chloride solution, followed by soaking in a glutaraldehyde solution to chemically cross-link, and cleaning and freeze-drying to obtain the 3D printed scaffold; sterilizing the 3D printed scaffold; seeding rBMSC suspension on the sterilized 3D printed scaffold at a concentration of at least 106 cells / well, and culturing rBMSC by using a low glucose DMEM with 10% FBS for 2 weeks; and taking out the scaffold to perform a decellularization treatment, and freeze-drying the decellularized 3D printed scaffold to obtain the 3D printed bone defect repair scaffold loaded with extracellular matrix of mesenchymal stem cells.

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and / or a detected location of the user.

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis EF-1 capable of reducing blood lipid, a microbial preparation and application of the enterococcus faecalis EF-1. The enterococcus faecalis EF-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 27, 2024, and the preservation number is CGMCC No.32097. The enterococcus faecalis EF-1 is named as enterococcus faecalis EF-1. The enterococcus faecalis EF-1 has the functions of: (1) relieving the weight increase speed of animals, reducing body weight gain, and preventing, relieving or treating obesity; (2) the contents of triglyceride, cholesterol and low-density lipoprotein cholesterol in liver and serum are reduced; (3) the liver function is protected, and the contents of ALT and AST in serum and liver are reduced; (4) liver lipid deposition and lesion are relieved; (5) relieving adipose tissue hypertrophy; (6) preventing, relieving or treating metabolic syndrome; (7) reducing blood sugar, improving insulin resistance and relieving diabetes mellitus; 8, increasing the content of short-chain fatty acid; and (9) regulating intestinal flora.

A system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (CGM) data.

The invention provides cinnamon fine dried noodles with a low glycemic index and a preparation method of the cinnamon fine dried noodles, and belongs to the technical field of food processing. The low-GI cinnamon fine dried noodles provided by the invention are prepared from the following raw materials in parts by weight: 100 to 120 parts of flour, 0.5 to 2.5 parts of cinnamon active extract, 1.0 to 2.0 parts of table salt, 0.2 to 1.0 part of dietary alkali and 35 to 55 parts of water. By adding the cinnamon active extract, the nutritional value of traditional wheat fine dried noodles is considered, and the advantages of low-GI food are achieved. While the addition amount of the flour is not reduced, the flavor of the fine dried noodles is enriched, and the hypoglycemic health-care function of the fine dried noodles is also improved.

In an embodiment, a system for of preventively treating hypoglycemia includes a continuous glucose monitoring (CGM) sensor system configured to generate measurements associated with a current glucose level of a patient. The system further includes one or more memories comprising executable instructions and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to receive, from the CGM sensor system, one or more measurements associated with the current glucose level of the patient and compute a sequence of preventive hypoglycemia treatments over a future time period based on the one or more measurements and a prediction of glucose control to be produced by the sequence. The one or more processors are further configured to prompt the patient with a first preventive hypoglycemia treatment in the sequence of preventive hypoglycemia treatments.

The invention belongs to the technical field of assisted reproduction, and particularly relates to a glucose slow-release structure used in an embryo in-vitro culture solution, a preparation process and a use method. The glucose slow-release structure comprises at least one inner layer containing glucose and a biodegradable material outer layer wrapping the inner layer, and the biodegradable material outer layer comprises a matrix with a plurality of micropores and at least one sealing material layer used for sealing pores of the micropores. According to the invention, gradient release from low sugar in the cleavage stage to high sugar in the blastocyst stage is realized, midway liquid change or artificial sugar supplement is not needed, the operation is obviously simplified, and pollution and mechanical stress risks are reduced.

Insulin therapy revolutionized the care of patients with diabetes, yet insulin-induced hypoglycemia remains a serious life-threatening complication of insulin therapy. Glucagon is a highly effective treatment for hypoglycemia; however, current dosage forms remain under-utilized due to poor patient compliance. High-density, readily soluble, and thermostable solid glucagon formulations applied with painless, application-specific microneedle-patches can treat hypoglycemia in type 1 diabetes patients who are awake or asleep. On-demand patches can prevent or treat mild hypoglycemia during the day, and enzyme-driven hypoglycemia-responsive patches can release glucagon autonomously during the night. These patches have excellent in vitro glucagon stability, loading, and release kinetics and can treat hypoglycemia in diabetic humans and animals. These delivery systems enable new modes of glucagon therapy, thereby expanding the clinical role of glucagon beyond the emergency setting.

The present invention provides low glycemic index (GI) total nutrition formula emulsion and a preparation method therefor. The low GI total nutrition formula emulsion comprises the following raw material components in parts by weight: 10-14 parts of carbohydrates, 4-5 parts of calcium caseinate, 1.3-2 parts of dietary fiber, 0.1-0.15 part of sodium chloride, 0.1-0.12 part of sodium citrate, 0.1-0.15 part of potassium citrate, 0.15-0.2 part of magnesium chloride, 0.1-0.15 part of dipotassium hydrogen phosphate, 0.05-0.1 part of compound vitamins, 0.05-0.1 part of compound minerals, 2.5-3.6 parts of compound oil, 0.3-0.5 part of phospholipid, 0.2-0.5 part of medium chain triglyceride (MCT), 0.04-0.08 part of colloids. The preparation method comprises: preparing aqueous phases and oil phases from the raw materials step by step; mixing the aqueous phases and oil phases; and shearing, homogenizing and sterilizing the mixture to obtain the low GI total nutrition emulsion. The product features balanced and complete nutrition.

Disclosed herein are formulations (including sweet proteins and rare sugars) for improving the sweetness of low glycemic index rare sugars without altering the texture and flavor of the rare sugars and methods for improving the sweetness of rare sugars. More specifically, the present invention discloses methods for improving the sweetness of rare sugars without altering the sweetness profile, texture and flavor of the primary sugars. The invention also discloses the addition of Brazitame protein with liquid rare sugars at different temperatures during the synthesis of the rare sugars, before crystallization or before or after caramelization of the rare sugars, to increase sweetness. The Brazilian sweet protein increases the sweetness of rare sugars, but is not limited to D-psicose, D-tagatose, D-allose, isomaltulose, trehalose, sorbose, pinose, leucobiose and the like. The invention also provides for the evaluation of non-nutritional sweeteners (such as aspartame, acesulfame, sodium cyclamate, neotame, saccharin, sucralose, stevioside, etc.), as each has a limitation of taste quality if used with rare sugars. However, the use of Brazilian sweet protein does not alter the flavor and texture of rare sugars, and the taste profile matches sucrose.

The invention belongs to the technical field of food processing, particularly relates to a low-GI high-fiber wholewheat biscuit and a preparation method thereof, and further relates to application of the low-GI high-fiber wholewheat biscuit as a low-glycemic-index food to regulation of intestinal flora. The soluble dietary fiber inulin is added into the whole wheat flour, the processing characteristics of the whole wheat flour and dough are remarkably improved through the addition of the inulin, the color and luster of the biscuit are also remarkably improved, the prepared low-GI high-fiber whole wheat biscuit has good taste and good crispness, and the content of total dietary fibers in the biscuit is as high as 19%. The GL value of the low-GI high-fiber whole-wheat biscuit is only 8.20, the GI value is 50.24, the GL value and the GI value are obviously lower than those of whole-wheat biscuits, and the low-GI high-fiber whole-wheat biscuit belongs to low-blood-sugar-load food and has a better adjusting effect on intestinal flora and short-chain fatty acid compared with the whole-wheat biscuits.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

The invention relates to (Z)-5-hydroxy-3-methyl-pent-2-enamide and application thereof, in particular to a novel compound (Z)-5-hydroxy-3-methyl-pent-2-enamide extracted and separated from secondary metabolites of Fusarium acuminatum, the novel compound (Z)-5-hydroxy-3-methyl-pent-2-enamide is white powder, the molecular formula of the novel compound (Z)-5-hydroxy-3-methyl-pent-2-enamide is C6H11NO2, and a quasi-molecular ion peak given by a high-resolution mass spectrum is [2M + Na-CO] + 253.1543; the invention relates to an application of (Z)-5-hydroxy-3-methyl-pent-2-enamide in preparation of a medicine for reducing blood sugar, in particular to an application of (Z)-5-hydroxy-3-methyl-pent-2-enamide.

This invention relates to the field of beverage technology, specifically disclosing a low glycemic index health beverage rich in monk fruit leaf flavonoids. The beverage comprises main ingredients, which are composed of the following components by weight: 18-35 parts monk fruit leaf extract, 15-22 parts bitter melon extract, and 15-22 parts houttuynia cordata extract. This invention's low glycemic index health beverage, rich in monk fruit leaf flavonoids, utilizes the bioactivity of natural plant raw materials such as monk fruit leaves, bitter melon, and houttuynia cordata. Through a reasonable proportion of components, it is formulated into a compound beverage with high nutritional value, possessing health benefits such as anti-fatigue, antipyretic, anti-inflammatory, diuretic, and non-toxic effects. Furthermore, it is safe and non-toxic. Combined with monk fruit glycosides and erythritol as sweeteners, it has a good flavor while maintaining a low glycemic index, meeting the needs of people trying to reduce their sugar intake.

The invention relates to the field of food processing, and discloses starch gel and a preparation method thereof. The method comprises the following steps: mixing starch and water-soluble hemicellulose to obtain a mixed solution, and carrying out heat treatment on the mixed solution; wherein the mass ratio of the starch to the water-soluble hemicellulose is (8-15): 1; wherein in the starch, the mass of amylose accounts for more than 60wt% of the total mass of the starch. After the food containing the starch gel provided by the invention is eaten, the starch digestibility is obviously lower, the blood sugar rising degree is lower, and the starch gel provided by the invention is healthier and more suitable for being applied to food production.

The invention discloses hericium erinaceus hypoglycemic peptide as well as a preparation method and application thereof. The amino acid sequence of the hericium erinaceus hypoglycemic peptide is GRVVPAPIPR. Polypeptides are extracted and purified from hericium erinaceus sporocarp protein, an amino acid sequence of one of the peptides for reducing blood sugar is determined through LC-MS / MS, the inhibition rate of the peptide for alpha-amylase is 80.63% + / -0.23% through blood sugar reduction activity detection, the inhibition rate of the peptide for alpha-glucosidase is 70.77% + / -0.29%, the peptide can be used as a natural peptide for reducing blood sugar, and the peptide for reducing blood sugar can be used as a natural peptide for reducing blood sugar. Potential application prospects are realized in the fields of preparation of medicines for reducing blood sugar and the like.

The invention provides a production method for increasing the yield of maltose, which comprises the following steps: proportioning, liquefying and saccharifying, controlling the concentration of starch milk through proportioning, reducing the concentration of syrup, improving the flowability of a system, obtaining a liquefied liquid with a low DE value in the liquefying process, and simultaneously adjusting the pH values of different reaction steps, so that the yield of maltose is increased. Finally, after saccharification is completed, the ultrahigh malt syrup which is low in content of glucose, maltose trisaccharide, maltose trisaccharide or more and high in maltose content is obtained, and the highest maltose content can reach 93%.

The invention discloses prebiotic soft fried dough twists and a making method thereof, and belongs to the technical field of food. The fried dough twist disclosed by the invention is prepared from the following raw materials in parts by mass: 132 to 169.5 parts of a dough base material, 5 to 6 parts of resistant dextrin, 7 to 9 parts of fructo-oligosaccharide microcapsules, 6 to 8 parts of isomaltitol, 1.5 to 2 parts of stachyose, 0.5 to 1.0 part of soybean lecithin and 0.01 to 0.03 part of vitamin E. The prebiotic retention rate is synergistically increased through microcapsule coating and a making process, the aging resistance of the fried dough twist is improved through synergistic moisturizing of resistant dextrin and fructo-oligosaccharide microcapsules, white granulated sugar is partially replaced by isomaltitol, stachyose and other sugar parts with low glycemic index, and the taste of the fried dough twist is improved. And the resistant dextrin with high dietary fiber content and the fructo-oligosaccharide prebiotics are matched, so that the product not only meets the sweet taste requirement, but also meets the healthy diet pursuit of modern consumers on low sugar, high fiber and high prebiotics.

This invention discloses a low glycemic index (GI) Hericium erinaceus (monkey head mushroom) steamed bun, belonging to the field of food processing and functional food applications. By weight, it is prepared from the following raw materials: 45-55 parts all-purpose flour, 28-35 parts Hericium erinaceus extract powder, 0.3-0.35 parts yeast, 15-18 parts water, 0.3-0.6 parts oil, and 0.7-0.9 parts sugar. This invention partially replaces the flour with Hericium erinaceus extract powder, fully utilizing the multiple mechanisms of action of Hericium erinaceus polysaccharides in forming a viscous gel in the digestive tract to slow down the contact between amylase and substrate, inhibiting α-amylase and α-glucosidase activity, and improving intestinal microecology and enhancing insulin sensitivity through dietary fiber. This allows the product to meet the low-GI food standard (GI<55), effectively filling the gap in low-GI steamed buns with Hericium erinaceus functional components as the core active ingredient. It has significant application value in the fields of diabetes management, weight control, and healthy staple foods.

The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus acidophilus GOLDGUT-LA100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof. The Lactobacillus acidophilus GOLDGUT-LA100 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28398. The strain has strong acid resistance, can adapt to the digestive tract environment, and has high bile salt hydrolase activity. At the same time, in animal experiments, the strain significantly reduces blood glucose and serum cholesterol levels, reduces liver fat deposition, reduces adipose tissue inflammation, effectively reduces the weight, and has broad application prospects in the development of products for improving obesity, lowering lipid and lowering blood glucose.

Disclosed is use of a polypeptide in the preparation of drugs, foods, or health care products for treating obesity and comorbidities thereof, which belongs to the technical field of biological medicines. The polypeptide is a human GPR15L polypeptide or a mouse GPR15L polypeptide and a polypeptide conjugate thereof. The treatment of obesity includes: reducing fat accumulation, promoting fat thermogenesis and catabolism, increasing energy consumption, and reducing body weight. The obesity comorbidities include: chronic inflammation, fatty liver, steatohepatitis, metabolic diseases, cardiovascular and cerebrovascular diseases, osteoarticular diseases, Alzheimer's disease, depression, tumors, and skin diseases. A novel mechanism of action reduces blood glucose and body weight, thereby effectively treating obesity and comorbidities thereof.

Food and / or beverage additives are generally provided. In some embodiments, the additive comprises a sweetener (e.g., a healthy sweetener). The additives and / or sweeteners described herein may be useful when added a food and / or beverage e.g., to increase the sweetness of a food and / or beverage. In some embodiments, the additives and / or sweeteners may advantageously be used to reduce the sugar and / or caloric content of a food and / or beverage e.g., as compared to the food and / or beverage without the additive and / or sweetener or containing conventional sweeteners. Advantageously, the additives comprising the sweeteners described herein may be useful for providing a food and / or beverage having a relatively low glycemic index and / or a relatively low number of calories per serving.

The application discloses a recombinant protein, a DNA fragment, an expression vector, a preparation method of a transgenic lettuce and an oral hypoglycemic drug, relates to the technical field of biological medicines, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO:1.The recombinant protein, i.e., a human transferrin-proinsulin fusion protein, can utilize the natural combination of the human transferrin-transferrin receptor to mediate the endocytosis transport of proinsulin after being orally taken, pass through the intestinal tract to enter the blood system, and reduce blood sugar.According to animal experiments, the effect of the recombinant protein is close to that of natural insulin, and the recombinant protein realizes oral delivery of insulin.

The invention discloses a compound having an effect of improving insulin resistance or a pharmaceutical salt thereof, and a preparation method and application thereof, and relates to the technical field of chemical drugs; the invention discloses a plurality of compounds having an effect of improving insulin resistance obtained by extraction and separation from red ganoderma lucidum, and the compounds have the effects of activating Akt or phosphorylation of insulin receptor substrate 1, promoting glucose uptake in a dose-dependent manner, lowering blood sugar and reducing fat, indicating the value of the compounds in preparing drugs for preventing or treating diseases related to insulin resistance.

Methods of treating type 1 diabetes, improving cardiovascular health, delaying renal function decline, reducing the risk of cardiovascular death and reducing the risk of heart failure hospitalization, while minimizing adverse events such as diabetic ketoacidosis and severe hypoglycemia, using sodium-glucose cotransporter 2 (SGLT2) inhibitors are disclosed. In a preferred method, the SGLT2 inhibitor is sofogliflozin. Also disclosed are prescriptions for developing sofogliflozin and methods of administering sofogliflozin.

The invention discloses low glycemic index rice flour of a starch-fat-protein ternary complex, and relates to the technical field of food. The low-glycemic-index rice flour is prepared by mixing rice flour, lauric acid and beta lactoglobulin, the preparation process is simple and convenient to operate, the nutritional structure of traditional rice flour is optimized, the glycemic index is lower than that of the traditional rice flour, and the low-glycemic-index rice flour has good nutritional and health-care values.

A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.

Food and / or beverage additives are generally provided. In some embodiments, the additive comprises a sweetener (e.g., a healthy sweetener). The additives and / or sweeteners described herein may be useful when added a food and / or beverage e.g., to increase the sweetness of a food and / or beverage. In some embodiments, the additives and / or sweeteners may advantageously be used to reduce the sugar and / or caloric content of a food and / or beverage e.g., as compared to the food and / or beverage without the additive and / or sweetener or containing conventional sweeteners. Advantageously, the additives comprising the sweeteners described herein may be useful for providing a food and / or beverage having a relatively low glycemic index and / or a relatively low number of calories per serving.

The application discloses application of a hypoglycemic peptide in preparation of a medicine for inhibiting alpha-amylase and alpha-glucosidase activity. The hypoglycemic peptide is derived from Hericium erinaceus, and the amino acid sequence is AVFPSIVGRPR. The polypeptide is extracted and purified from Hericium erinaceus fruiting body protein, the amino acid sequence of one hypoglycemic peptide is determined by LC-MS / MS, the alpha-amylase inhibition rate is 71.86%±0.08% through hypoglycemic activity detection, and the alpha-glucosidase inhibition rate is 61.52%±0.15%, so the hypoglycemic peptide can be used as a natural hypoglycemic peptide and has a potential application prospect in the field of preparation of medicines for reducing blood sugar and the like.